<DOC>
	<DOC>NCT00832871</DOC>
	<brief_summary>The purpose of this study is to see if mifepristone prevents worsening of your cancer. Mifepristone is an antiprogesterone agent, a drug which blocks female hormones, that is commonly used for the termination of pregnancies. It has not been approved by the Food and Drug Administration for use in the treatment of cancer. It is unlicensed in the United States for your condition. However, previous work has indicated that mifepristone may be useful due to how it works. It is being made available for use in the United States for compassionate use through the Feminist Majority Foundation.</brief_summary>
	<brief_title>Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers</brief_title>
	<detailed_description>This is a compassionate use of mifepristone treatment for patients with conditions that could respond to an antiprogesterone agent, including: - Meningioma. - Breast cancer - Colon Cancer - Endometrial Stromal Sarcoma - Bilateral Chronic Central Serous Retinopathy - Cushing's Syndrome - Metastatic Adrenocortical Cancer - Ovarian Cancer - Other conditions as determined by the attending physicians</detailed_description>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>All patients 18 years of age or older. Patients must sign an informed consent. Patients should be in such a health condition in the opinion of the attending physician that with the administration of mifepristone benefits may outweigh risks. Pregnant women or nursing mothers are not eligible for this trial. Patients of child bearing potential must use adequate contraception.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Mifepristone</keyword>
	<keyword>RU-486</keyword>
	<keyword>Compassionate Use</keyword>
	<keyword>Antiprogesterone</keyword>
</DOC>